BetterLife Pharma Inc NT 20-F, filed Jun 1, 2022
BetterLife Pharma Inc. (BETRF)
| UNITED STATES | ||
| SECURITIES AND EXCHANGE COMMISSION | ||
| Washington, D.C. 20549 | ||
| FORM 12b-25 | SEC FILE NUMBER 333-161157 | |
| NOTIFICATION OF LATE FILING | CUSIP NUMBER 08772P202 |
| (Check one): | ☐ | Form 10-K | ☒ | Form 20-F | ☐ | Form 11-K | ☐ | Form 10-Q | ☐ | Form 10-D | ☐ | Form N-CEN | ☐ | Form N-CSR |
|
| For Period Ended: January 31, 2022 | |||
|
|
| |||
|
| ☐ | Transition Report on Form 10-K | ||
|
| ☐ | Transition Report on Form 20-F | ||
|
| ☐ | Transition Report on Form 11-K | ||
|
| ☐ | Transition Report on Form 10-Q | ||
|
|
| |||
|
| For the Transition Period Ended: N/A | |||
|
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
|
|
|
| If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
|
|
|
| PART I — REGISTRANT INFORMATION |
| BetterLife Pharma Inc. |
|
| Full Name of Registrant. |
|
|
|
|
|
|
|
| Former Name if Applicable |
|
|
|
|
| 1275 WEST 6th AVENUE, #300 |
|
| Address of Principal Executive Office (Street and Number) |
|
|
|
|
| VANCOUVER, BC V6H 1A6 |
|
| City, State and Zip Code: |
|
| PART II — RULES 12b-25(b) AND (c) |
|
|
| If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. |
|
|
| (a) | The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; |
|
|
|
| |
| ☒ |
| (b) | The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and |
|
|
| ||
|
|
| (c) | The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |
| PART III — NARRATIVE |
|
|
| The Registrant is unable to file its Annual Report on Form 20-F for the year ended January 31, 2022, within the prescribed time period as they are awaiting auditor completion and signoff of their financial statements. It is anticipated that the Annual Report on Form 20-F will be filed on or before the 15th calendar day following the prescribed due date. |
| PART IV — OTHER INFORMATION |
| (1) | Name and telephone number of person to contact in regard to this notification | ||||||||
| Moira Ong |
| (604) |
| 551-5178 | ||||
| (Name) |
| (Area Code) |
| (Telephone Number) | ||||
| (2) | Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). Yes ☒ No ☐ | ||||||||
|
| |||||||||
| (3) | Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? Yes ☐ No ☒ | ||||||||
|
| |||||||||
|
| If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made. | ||||||||
| 2 |
| BetterLife Pharma Inc. | |||||
| (Name of Registrant as Specified in Charter) | |||||
|
|
| ||||
| has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized. |
| ||||
|
|
| ||||
| Date: May 31, 2022 |
| By: | /s/ Moira Ong |
| |
|
|
|
| Moira Ong Chief Financial Officer |
| |
| 3 |